Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.60 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114528 | 0.80 | HRH3 (0.71) | HRH3HTR3A | |
| SCHEMBL2114693 | 0.79 | HRH3 (0.61) | HRH3ADORA2AHTR3ACYP3A4CYP2D6 | |
| SCHEMBL11096825 | 0.77 | CYP3A4 (0.52) | HRH3CYP3A4CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL1372914 | 0.75 | HRH3 (0.69) | HRH3CYP19A1 | |
| SCHEMBL2113936 | 0.75 | HRH3 (0.73) | HRH3 | |
| SCHEMBL4064419 | 0.74 | HTR3A (0.70) | HRH3ADORA2AHTR3ACYP3A4CYP2D6 | |
| SCHEMBL1373281 | 0.74 | HTR3A (0.70) | HRH3ADORA2AHTR3ACYP3A4CYP2D6 | |
| SCHEMBL31698269 | 0.73 | HRH3 (0.45) | HRH3BRD4CYP3A4 | |
| SCHEMBL4098362 | 0.72 | DRD2 (0.55) | CYP3A4CYP2D6CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL11093336 | 0.71 | KCNA3 (0.52) | HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | HRH3 1/4885BRD4 492/4885ADORA2A 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.